These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 34379306)

  • 1. Healthy Volunteer Studies in the Development of Anticancer Drugs with Genotoxic Findings.
    Omes-Smit G; Garsen M; Zwiers A
    Ther Innov Regul Sci; 2022 Jan; 56(1):76-84. PubMed ID: 34379306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reviewing the role of healthy volunteer studies in drug development.
    Karakunnel JJ; Bui N; Palaniappan L; Schmidt KT; Mahaffey KW; Morrison B; Figg WD; Kummar S
    J Transl Med; 2018 Dec; 16(1):336. PubMed ID: 30509294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Decade of Marketing Authorization Applications of Anticancer Drugs in the European Union: An Analysis of Procedural Timelines.
    Garsen M; Steenhof M; Zwiers A
    Ther Innov Regul Sci; 2021 Jul; 55(4):633-642. PubMed ID: 33543409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anticancer Drug Development: The Way Forward.
    Connors T
    Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The comet assay with multiple mouse organs: comparison of comet assay results and carcinogenicity with 208 chemicals selected from the IARC monographs and U.S. NTP Carcinogenicity Database.
    Sasaki YF; Sekihashi K; Izumiyama F; Nishidate E; Saga A; Ishida K; Tsuda S
    Crit Rev Toxicol; 2000 Nov; 30(6):629-799. PubMed ID: 11145306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Healthy volunteers in first-in-human oncology drug development for small molecules.
    de Las Heras B; Bouyoucef-Cherchalli D; Reeve L; Reichl A; Mandarino D; Flach S; Vidal L; van Brummelen EMJ; Steeghs N
    Br J Clin Pharmacol; 2022 Feb; 88(4):1773-1784. PubMed ID: 34558113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Post-marketing research and its outcome for novel anticancer agents approved by both the FDA and EMA between 2005 and 2010: A cross-sectional study.
    Zeitoun JD; Baron G; Vivot A; Atal I; Downing NS; Ross JS; Ravaud P
    Int J Cancer; 2018 Jan; 142(2):414-423. PubMed ID: 28929484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Approval of Cancer Drugs With Uncertain Therapeutic Value: A Comparison of Regulatory Decisions in Europe and the United States.
    Salcher-Konrad M; Naci H; Davis C
    Milbank Q; 2020 Dec; 98(4):1219-1256. PubMed ID: 33021339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adaptive clinical trial designs for European marketing authorization: a survey of scientific advice letters from the European Medicines Agency.
    Elsäßer A; Regnstrom J; Vetter T; Koenig F; Hemmings RJ; Greco M; Papaluca-Amati M; Posch M
    Trials; 2014 Oct; 15():383. PubMed ID: 25278265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of Companion Diagnostics in Scientific Advice and Drug Marketing Authorization Applications by the European Medicines Agency.
    Maliepaard M; Nibi P; Nibi G; Pasmooij AMG
    Front Med (Lausanne); 2022; 9():893028. PubMed ID: 35602486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oblimersen: Augmerosen, BCL-2 antisense oligonucleotide - Genta, G 3139, GC 3139, oblimersen sodium.
    Drugs R D; 2007; 8(5):321-34. PubMed ID: 17767397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The evidence base for psychotropic drugs approved by the European Medicines Agency: a meta-assessment of all European Public Assessment Reports.
    Erhel F; Scanff A; Naudet F
    Epidemiol Psychiatr Sci; 2020 Apr; 29():e120. PubMed ID: 32336312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monitoring evidence on overall survival benefits of anticancer drugs approved by the European Medicines Agency between 2009 and 2015.
    Grössmann N; Robausch M; Rosian K; Wild C; Simon J
    Eur J Cancer; 2019 Mar; 110():1-7. PubMed ID: 30735832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Qualitative Study on the Differences Between Trial Populations and the Approved Therapeutic Indications of Antineoplastic Agents by 3 Regulatory Agencies From 2010 to 2018.
    Sumi E; Asada R; Lu Y; Ito-Ihara T; Grimes KV
    Clin Ther; 2020 Feb; 42(2):305-320.e0. PubMed ID: 32008723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer drugs for solid tumors approved by the EMA since 2014: an overview of pivotal clinical trials.
    Lasala R; Logreco A; Romagnoli A; Santoleri F; Musicco F; Costantini A
    Eur J Clin Pharmacol; 2020 Jun; 76(6):843-850. PubMed ID: 32125472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacogenetic-Pharmacokinetic Interactions in Drug Marketing Authorization Applications via the European Medicines Agency Between 2014 and 2017.
    Maliepaard M; Toiviainen T; De Bruin ML; Meulendijks D
    Clin Pharmacol Ther; 2020 Aug; 108(2):338-349. PubMed ID: 32236952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current regulatory perspectives on genotoxicity testing for botanical drug product development in the U.S.A.
    Wu KM; Dou J; Ghantous H; Chen S; Bigger A; Birnkrant D
    Regul Toxicol Pharmacol; 2010 Feb; 56(1):1-3. PubMed ID: 19782117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulatory approval pathways for anticancer drugs in Japan, the EU and the US.
    Nagai S; Ozawa K
    Int J Hematol; 2016 Jul; 104(1):73-84. PubMed ID: 27084259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of validated and nonvalidated surrogate endpoints in two European Medicines Agency expedited approval pathways: A cross-sectional study of products authorised 2011-2018.
    Schuster Bruce C; Brhlikova P; Heath J; McGettigan P
    PLoS Med; 2019 Sep; 16(9):e1002873. PubMed ID: 31504034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conflicting meal recommendations for oral oncology drugs: pose risks to patient care?
    Yu G; Wu DN; Gong Y; Li GF; Zhou HH
    Eur J Clin Pharmacol; 2018 Jun; 74(6):833-842. PubMed ID: 29536134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.